Neuvasq’s most advanced programs are NVQ401, a first-in-class bispecific antibody that selectively activates the Wnt/β-catenin signaling cascade via Gpr124/Lrp6, and NVQ501, a fusion of a Gpr124/Lrp6 ...
Dive into The Register's online archive of incisive tech news reporting, features, and analysis dating back to 1998 ...